Document is current
Any future updates will be listed below
-
Authors
Gulen, Ayse Ece http://orcid.org/0000-0002-8024-8772
Rudraboina, Rakesh http://orcid.org/0000-0002-4487-9091
Tarique, Mohammad http://orcid.org/0000-0002-8829-3041
Ulker, Vahap http://orcid.org/0000-0002-8876-2119
Shirwan, Haval http://orcid.org/0000-0002-1657-9470
Yolcu, Esma S. http://orcid.org/0000-0002-4312-8798
-
Funding
Funding for this research was provided by:
U.S. Department of Defense (LC190524, LC190524)
- License Information
-
More Information
Article History
Received: 13 April 2023
Accepted: 23 July 2023
First Online: 22 August 2023
Declarations
:
: H.S. is CEO of Fascure Therapeutics, LLC, and the Scientific Co-Founder, stockholder, and member of SAB for iTolerance, Inc. E.S.Y. is a consultant for iTolerance. The remaining authors declare no conflict of interest.
